CAR-T Meeting 2023 | Using engineered T-cells to suppress acute GvHD and leukemia relapse after alloSCT
Maksim Mamonkin
• 10 Feb 2023
In this video, Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, shares some insights into ongoing research exploring the use of engineered T-cells to prevent acute graft-versus-host disease (GvHD) and leukemia relapse after allogeneic stem cell transplantation (alloSCT). Dr Mamonkin highlights findings from a pre-clinical study evaluating OX40-targeting T-cells, which were able to eradicate disease and prevent GvHD, and may be further explored in a clinical setting. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Fate
Royalties and License fees: Fate, Allogene, March Bio
Equity: March Bio
Consulting: March Bio
